

# CCL22 Antibody (Center) Blocking Peptide

Synthetic peptide Catalog # BP16351c

### **Specification**

## **CCL22 Antibody (Center) Blocking Peptide - Product Information**

Primary Accession

000626

## CCL22 Antibody (Center) Blocking Peptide - Additional Information

**Gene ID 6367** 

#### **Other Names**

C-C motif chemokine 22, CC chemokine STCP-1, MDC(1-69), Macrophage-derived chemokine, Small-inducible cytokine A22, Stimulated T-cell chemotactic protein 1, MDC(3-69), MDC(5-69), MDC(7-69), CCL22, MDC, SCYA22

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## **CCL22 Antibody (Center) Blocking Peptide - Protein Information**

Name CCL22

Synonyms MDC, SCYA22

### **Function**

May play a role in the trafficking of activated/effector T- lymphocytes to inflammatory sites and other aspects of activated T- lymphocyte physiology. Chemotactic for monocytes, dendritic cells and natural killer cells. Mild chemoattractant for primary activated T- lymphocytes and a potent chemoattractant for chronically activated T- lymphocytes but has no chemoattractant activity for neutrophils, eosinophils, and resting T-lymphocytes. Binds to CCR4. Processed forms MDC(3-69), MDC(5-69) and MDC(7-69) seem not be active.

### **Cellular Location**

Secreted.

## **Tissue Location**

Highly expressed in macrophage and in monocyte- derived dendritic cells, and thymus. Also found in lymph node, appendix, activated monocytes, resting and activated macrophages. Lower expression in lung and spleen. Very weak expression in small intestine In lymph node expressed in



101. 000.01 0.1000 1 ax. 000.010.1000

a mature subset of Langerhans' cells (CD1a+ and CD83+). Expressed in Langerhans' cell histiocytosis but not in dermatopathic lymphadenopathy. Expressed in atopic dermatitis, allergic contact dermatitis skin, and psoriasis, in both the epidermis and dermis.

## **CCL22 Antibody (Center) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

#### • Blocking Peptides

CCL22 Antibody (Center) Blocking Peptide - Images

## CCL22 Antibody (Center) Blocking Peptide - Background

CCL22 is one of several Cys-Cys (CC) cytokine genesclustered on the q arm of chromosome 16. Cytokines are a family ofsecreted proteins involved in immunoregulatory and inflammatoryprocesses. The CC cytokines are proteins characterized by twoadjacent cysteines. The cytokine encoded by this gene displayschemotactic activity for monocytes, dendritic cells, natural killercells and for chronically activated T lymphocytes. It also displaysa mild activity for primary activated T lymphocytes and has nochemoattractant activity for neutrophils, eosinophils and resting Tlymphocytes. The product of this gene binds to chemokine receptorCCR4. This chemokine may play a role in the trafficking ofactivated T lymphocytes to inflammatory sites and other aspects ofactivated T lymphocyte physiology.

### CCL22 Antibody (Center) Blocking Peptide - References

Toulza, F., et al. J. Immunol. 185(1):183-189(2010)Maruyama, T., et al. Dis. Esophagus 23(5):422-429(2010)Schuurhof, A., et al. Pediatr. Pulmonol. 45(6):608-613(2010)Wu, C., et al. Respirology 15(3):522-529(2010)Davila, S., et al. Genes Immun. 11(3):232-238(2010)